NASDAQ: ACXP - Acurx Pharmaceuticals, Inc.

Yield per half year: +8.29%
Sector: Healthcare

Share chart Acurx Pharmaceuticals, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections.

More details
It is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. The company was incorporated in 2017 and is headquartered in Staten Island, New York.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Цена ао 2.08
EBITDA -0.0059
P/BV 3.56
EV/EBITDA 0.4187
ISIN US00510M1045
Сайт https://www.acurxpharma.com
Число акций ао 0.01267 млрд
Валюта usd
IPO date 2021-06-25
Sector Health Care
Industry Biotechnology
Валюта отчета usd
Change price per day: -1.88% (2.13)
Change price per week: +8.85% (1.92)
Change price per month: -1.88% (2.13)
Change price per 3 month: +3.47% (2.02)
Change price per half year: +8.29% (1.93)
Change price per year: +8.85% (1.92)
Change price per 3 year: -52.34% (4.385)
Change price per year to date: -46.27% (3.89)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 10.05 1
P/E 0 0
EV/EBITDA -2.7 0
Total: 2.63

Efficiency

Title Value Grade
ROA, % -189.1 0
ROE, % -312.38 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA 0 10
Total: 9.8

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % 147.08 10
Yield EPS, % 45.51 6
Total: 7.2
More

Institutions Volume Share, %
Vanguard Group Inc 406387 2.58
Prospect Financial Services LLC 255150 1.62
Geode Capital Management, LLC 112132 0.71
Blackrock Inc. 63126 0.4
Osaic Holdings Inc 57250 0.36
Susquehanna International Group, LLP 53553 0.34
State Street Corporation 28566 0.18
Td Waterhouse Canada Inc. 18656 0.12
Northern Trust Corporation 17153 0.11
Morgan Stanley 16201 0.1

ETF Share, % Profitability for 1 year, % Dividends, %
iShares Micro-Cap ETF 0.00555 36.318555985322 1.54048



Head Job title Payment Year of birth
Mr. Robert J. DeLuccia Co-Founder & Executive Chairman 701.54k 1946 (78 years)
Mr. Robert G. Shawah CPA, CPA Co-Founder & CFO 470.29k 1967 (57 years)
Mr. David P. Luci CPA, Esq., J.D. Co-Founder, President, CEO, Corporate Secretary & Director 1967 (57 years)

Address: United States, Staten Island. NY, 259 Liberty Avenue - open in Google maps, open in Yandex maps
Website: https://www.acurxpharma.com